; GAO study on gaps in Medicaid coverage for pregnant and postpartum women with substance use disorder. Sec. 1006. Medicaid health homes for substance-use-disorder Medicaid enrollees. Sec. 1007. Caring recovery for infants and babies. Sec. 1008. Peer support enhancement and evaluation review. Sec. 1009. Medicaid substance use disorder treatment via telehealth. Sec. 1010. Enhancing patient access to non-opioid treatment options. Sec. 1011. Assessing barriers to opioid use disorder treatment. Sec. 1012. Help for moms and babies. Sec. 1013. Securing flexibility to treat substance use disorders. Sec. 1014. MACPAC study and report on MAT utilization controls under State Medicaid programs. Sec. 1015. Opioid addiction treatment programs enhancement. Sec. 1016. Better data sharing to combat the opioid crisis. Sec. 1017. Report on innovative State initiatives and strategies to provide housing-related services and supports to individuals struggling with substance use disorders under Medicaid. Sec. 1018. Technical assistance and support for innovative State strategies to provide housing-related supports under Medicaid. Title II—Medicare Provisions to Address the Opioid Crisis Sec. 2001. Expanding the use of telehealth services for the treatment of opioid use disorder and other substance use disorders. Sec. 2002. Comprehensive screenings for seniors. Sec. 2003. Every prescription conveyed securely. Sec. 2004. Requiring prescription drug plan sponsors under Medicare to establish drug management programs for at-risk beneficiaries. Sec. 2005. Medicare coverage of certain services furnished by opioid treatment programs. Sec. 2006. Encouraging appropriate prescribing under Medicare for victims of opioid overdose. Sec. 2007. Automatic escalation to external review under a Medicare part D drug management program for at-risk beneficiaries. Sec. 2008. Suspension of payments by Medicare prescription drug plans and MA–PD plans pending investigations of credible allegations of fraud by pharmacies. Title III—FDA and Controlled Substance